Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Whyte

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Bone|November 28, 2017
Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5)Ghada A Otaify, Michael P Whyte, Gary S Gottesman, et al.
The American Journal of Clinical Nutrition|January 5, 2002
Elevated plasma 4-pyridoxic acid in renal insufficiencyStephen P Coburn, Robert D Reynolds, J Dennis Mahuren, et al.
The Journal of Clinical Investigation|September 17, 2005
MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO)Ann M Kennedy, Masaki Inada, Stephen M Krane, et al.
Nature Genetics|December 11, 2012
Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3M Andrew Nesbit, Fadil M Hannan, Sarah A Howles, et al.
The Journal of Clinical Endocrinology and Metabolism|May 9, 2022
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M Ward, Francis H Glorieux, Michael P Whyte, et al.
Bone|April 25, 2017
Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRASMichael P Whyte, Malachi Griffith, Lee Trani, et al.
Human Mutation|February 24, 2011
COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfectaKatarina Lindahl, Aileen M Barnes, Nadja Fratzl-Zelman, et al.
JBMR Plus|May 1, 2024
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension periodLeanne M Ward, Wolfgang Högler, Francis H Glorieux, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Bone|November 28, 2017
Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5)Ghada A Otaify, Michael P Whyte, Gary S Gottesman, et al.
The American Journal of Clinical Nutrition|January 5, 2002
Elevated plasma 4-pyridoxic acid in renal insufficiencyStephen P Coburn, Robert D Reynolds, J Dennis Mahuren, et al.
The Journal of Clinical Investigation|September 17, 2005
MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO)Ann M Kennedy, Masaki Inada, Stephen M Krane, et al.
Nature Genetics|December 11, 2012
Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3M Andrew Nesbit, Fadil M Hannan, Sarah A Howles, et al.
The Journal of Clinical Endocrinology and Metabolism|May 9, 2022
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M Ward, Francis H Glorieux, Michael P Whyte, et al.
Bone|April 25, 2017
Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRASMichael P Whyte, Malachi Griffith, Lee Trani, et al.
Human Mutation|February 24, 2011
COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfectaKatarina Lindahl, Aileen M Barnes, Nadja Fratzl-Zelman, et al.
JBMR Plus|May 1, 2024
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension periodLeanne M Ward, Wolfgang Högler, Francis H Glorieux, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
Pageof 17